3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Motor Activity
2
Stomach Neoplasms
1
Lung Neoplasms
1
Hodgkin Disease
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
56
enzalutamide
44
Specimen Handling
37
apalutamide
35
Androgen Antagonists
35
Abiraterone Acetate
29
Prednisone
27
Radiosurgery
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
21
Radiotherapy
21
Leuprolide
20
Biopsy
16
relugolix
14
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
14
gallium 68 PSMA-11
12
Triptorelin Pamoate
12
Surveys and Questionnaires
12
Radiation
12
Gonadotropin-Releasing Hormone
12
X-Rays
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
10
cabazitaxel
9
bicalutamide
9
Standard of Care
9
Nivolumab
9
Goserelin
9
Carboplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
High-Intensity Interval Training
×
90 days
×
Clear all
NCT04558398
2026-04-29
ICCE-Mito
University of Nottingham
Phase NA
Completed
15 enrolled
NCT07518888
2026-04-09
ESCAPE
University of Miami
Phase NA
Not yet recruiting
49 enrolled